These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32749113)

  • 21. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.
    Zuckerman V; Sokolov E; Swet JH; Ahrens WA; Showlater V; Iannitti DA; Mckillop IH
    Oncotarget; 2016 Jan; 7(3):2951-67. PubMed ID: 26701886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.
    Reinartz S; Lieber S; Pesek J; Brandt DT; Asafova A; Finkernagel F; Watzer B; Nockher WA; Nist A; Stiewe T; Jansen JM; Wagner U; Konzer A; Graumann J; Grosse R; Worzfeld T; Müller-Brüsselbach S; Müller R
    Mol Oncol; 2019 Feb; 13(2):185-201. PubMed ID: 30353652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer.
    Dacheux MA; Norman DD; Tigyi GJ; Lee SC
    Pharmacol Ther; 2023 May; 245():108414. PubMed ID: 37061203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
    Lee Z; Swaby RF; Liang Y; Yu S; Liu S; Lu KH; Bast RC; Mills GB; Fang X
    Cancer Res; 2006 Mar; 66(5):2740-8. PubMed ID: 16510595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysophosphatidic Acid Signaling in Diabetic Nephropathy.
    Lee JH; Kim D; Oh YS; Jun HS
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
    Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
    Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.
    Radhakrishnan R; Ha JH; Jayaraman M; Liu J; Moxley KM; Isidoro C; Sood AK; Song YS; Dhanasekaran DN
    Cancer Lett; 2019 Feb; 442():464-474. PubMed ID: 30503552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
    Fang X; Gaudette D; Furui T; Mao M; Estrella V; Eder A; Pustilnik T; Sasagawa T; Lapushin R; Yu S; Jaffe RB; Wiener JR; Erickson JR; Mills GB
    Ann N Y Acad Sci; 2000 Apr; 905():188-208. PubMed ID: 10818454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of LPA in ovarian cancer development and progression.
    Pua TL; Wang FQ; Fishman DA
    Future Oncol; 2009 Dec; 5(10):1659-73. PubMed ID: 20001802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.
    Hu YL; Tee MK; Goetzl EJ; Auersperg N; Mills GB; Ferrara N; Jaffe RB
    J Natl Cancer Inst; 2001 May; 93(10):762-8. PubMed ID: 11353786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
    Sengupta S; Kim KS; Berk MP; Oates R; Escobar P; Belinson J; Li W; Lindner DJ; Williams B; Xu Y
    Oncogene; 2007 May; 26(20):2894-901. PubMed ID: 17130843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysophosphatidic Acid and Hematopoiesis: From Microenvironmental Effects to Intracellular Signaling.
    Lin KH; Chiang JC; Ho YH; Yao CL; Lee H
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LPAR2 and LPAR4 are the Main Receptors Responsible for LPA Actions in Ovarian Endometriotic Cysts.
    Kowalczyk-Zieba I; Woclawek-Potocka I; Wasniewski T; Boruszewska D; Grycmacher K; Sinderewicz E; Staszkiewicz J; Wolczynski S
    Reprod Sci; 2019 Jan; 26(1):139-150. PubMed ID: 29621954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
    Pustilnik TB; Estrella V; Wiener JR; Mao M; Eder A; Watt MA; Bast RC; Mills GB
    Clin Cancer Res; 1999 Nov; 5(11):3704-10. PubMed ID: 10589790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of lysophosphatidic acid receptors (LPARs) in buffalo uterus demonstrated upregulation of LPAR1 and LPAR6 in early pregnancy.
    Sadam A; Parida S; Padol AR; Verma AD; Baba NA; Khuman WM; Srivastava V; Panigrahi M; Singh TU; Sarkar SN
    Theriogenology; 2017 Sep; 99():90-97. PubMed ID: 28708504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
    Tanyi J; Rigó J
    Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma.
    Sokolov E; Eheim AL; Ahrens WA; Walling TL; Swet JH; McMillan MT; Simo KA; Thompson KJ; Sindram D; McKillop IH
    J Surg Res; 2013 Mar; 180(1):104-13. PubMed ID: 23182454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.
    Lizalek J; McKenna T; Huegel K; Marsh S; Carolan A; Kobliska A; Heying E; Gardner N; Miller G; Kotecki A; Henningsen M; Lundt A; Farley J; Ellerbroek SM
    Anticancer Res; 2015 Oct; 35(10):5263-70. PubMed ID: 26408685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
    Mahanivong C; Chen HM; Yee SW; Pan ZK; Dong Z; Huang S
    Oncogene; 2008 Feb; 27(9):1273-80. PubMed ID: 17724468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2).
    Huang MC; Lee HY; Yeh CC; Kong Y; Zaloudek CJ; Goetzl EJ
    Oncogene; 2004 Jan; 23(1):122-9. PubMed ID: 14712217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.